INTRODUCTION
============

*Helicobacter pylori* infection affects 54.4% of population in Korea \[[@b1-kjim-2018-054]\]. *H. pylori* infection can cause chronic gastritis, peptic ulcer disease (PUD), mucosa-associated lymphoid tissue lymphoma, and gastric cancer \[[@b2-kjim-2018-054],[@b3-kjim-2018-054]\]. Currently, most guidelines recommend a triple therapy consisting of a proton pump inhibitor (PPI) and two antibiotics (clarithromycin \[CAM\] and amoxicillin) as the first-line treatment for *H. pylori* eradication.

Nonetheless, the eradication rate of this regimen has decreased to an unacceptable level in Korea. It means that the eradication rate is below 80% according to intention-to-treat (ITT) analysis and below 90% by the per-protocol (PP) analysis \[[@b4-kjim-2018-054],[@b5-kjim-2018-054]\]. Despite the disappointing results, the Korean medical insurance system still considers the CAM-based triple therapy as the first-line treatment. A lack of sufficient evidence is the reason why the CAM-based regimen is not changed to other treatment regimens.

The eradication failure is influenced by host-related, bacterial, and environmental factors \[[@b6-kjim-2018-054],[@b7-kjim-2018-054]\]. CAM resistance is considered the most important factor of eradication failure \[[@b8-kjim-2018-054]\]. The CAM resistance rate is constantly increasing worldwide and varies substantially by region \[[@b9-kjim-2018-054],[@b10-kjim-2018-054]\]. It has been reported that the CAM resistance rate gradually increased from 17.2% to 23.7% between 2003 and 2012 in Korea \[[@b11-kjim-2018-054]\]. As a host factor, the *CYP2C19* polymorphism is also related to the *H. pylori* eradication rate because cytochrome P450 2C19 (CYP2C19) is involved in PPI metabolism \[[@b12-kjim-2018-054]\]. The rapid metabolizer (RM) genotype of CYP2C19 can be unfavorable for eradication because of low bioavailability of PPI. The roles of other factors including age, gender, the body mass index (BMI), cigarette smoking, alcohol intake, and systemic diseases are still controversial \[[@b5-kjim-2018-054],[@b13-kjim-2018-054],[@b14-kjim-2018-054]\].

The aim of the present study was to determine whether CAM resistance, the *CYP2C19* genotype, and clinical parameters can affect *H. pylori* eradication in a Korean population.

METHODS
=======

Patients and study protocol
---------------------------

We consecutively enrolled a total of 203 *H. pylori*-positive patients with chronic gastritis from September 2014 to August 2015 at Kyung Hee University Hospital, Seoul, Korea. The participants were excluded from the study if they had a PUD, gastric cancer, previous gastrectomy, severe underlying diseases, or received antibiotics or PPI within 4 weeks \[[@b15-kjim-2018-054]\]. At the first time of enrollment, we tried to include patients with PUD and chronic gastritis, but the number of *H. pylori*-related PUD cases was much smaller relative to chronic gastritis. Therefore, we included only chronic atrophic or nonatrophic gastritis. All the participants received a diagnosis of *H. pylori* infection by a rapid urease test or detection of *H. pylori* genomic DNA from gastric mucosal tissues.

We collected data including age, gender, cigarette smoking, alcohol intake, salt in the diet, family history of gastric cancer, BMI, hypertension, and diabetes. Although we tried to acquire prior history of antibiotic use, most subjects did not remember the name or the amount used of antibiotics. All the patients were prescribed the triple regimen consisting of a standard dose of PPI (pantoprazole), 1 g of amoxicillin, and 0.5 g of CAM twice daily for 7 days. Four weeks after the end of eradication therapy, the ^13^C-urea breath test was performed to confirm successful eradication of *H. pylori* infection. A week after completion of treatment, information about adverse events and compliance was collected from the outpatient department by means of telephone interviews. When patients had consumed more than 85% of the study medications, compliance was considered satisfactory. The adverse events were metallic taste, diarrhea, nausea, epigastric discomfort, urticaria, and headache. All the patients provided written informed consent prior to enrollment. The Institutional Review Board of the Kyung Hee University Hospital approved the study protocol (KMC IRB 1427-01).

CAM resistance test
-------------------

It is known that the mutation of 23S rRNA results in increased antibiotic resistance \[[@b16-kjim-2018-054]\]. CAM resistance of *H. pylori* was determined by analysis of the A2142G or A2143G mutation in 23S rRNA. *H. pylori* genomic DNA was extracted from two biopsy specimens of the antrum and body collected during endoscopy. DNA was amplified by Seeplex Home-brew primer mix of the Seeplex ClaR-*H. pylori* polymerase chain reaction (PCR) kit (Seegene Inc., Seoul, Korea) that was developed using the dual-priming oligonucleotide system to detect the A2142G or A2143G mutation.

*CYP2C19* genotyping
--------------------

The genotyping of *CYP2C19* was conducted using PCR with restriction fragment length polymorphism \[[@b17-kjim-2018-054]\]. To detect the polymorphism of *CYP2C19* in exon 5, we designed the sense (5′-AATTACAACCAGAGCTTGGC-3′) and antisense primers (5′-TATCACTTTCCATAAAAGCAAG-3′). In exon 4, we used the sense (5′-GCTTCACCCTGTGATCCCAC-3′) and antisense primer (5′-TCAGGGCTTGGTCAATATAG-3′). The PCR product containing G681A in exon 5 was digested by incubation with Sma I at 37°C for 3 hours, resulting in two bands (120 and 49 bp) for the G/G genotype (wild), three bands (169, 120, and 49 bp) for the G/A genotype (heterozygote), and one band of 169 bp for the A/A genotype (mutant type). The PCR product containing G636A in exon 4 was digested by incubation with BamH I at 37°C for 3 hours, resulting in two bands (155 and 93 bp) for the G/G genotype (wild type), three bands (248, 155, and 93 bp) for the G/A genotype (heterozygote), and one band of 248 bp for the A/A genotype (mutant type). The patients were classified into three groups by *CYP2C19* genotype: RM had exon 5, wild type/exon 4, wild type; intermediate metabolizers (IMs) had exon 5, wild type/exon 4, heterozygote or exon 5, heterozygote/exon 4, wild type; and poor metabolizers (PMs) had both mutated alleles.

Data analysis
-------------

Eradication was evaluated by the ITT and PP analyses with 95% confidence intervals (CIs). Continuous variables are expressed as mean ± standard deviation, and categorical variables as percentages. Student *t* test for parametric data and the Mann-Whitney *U* test for nonparametric data were used for comparisons of the means of continuous variables, whereas differences in categorical variables were assessed using chi-square or Fisher exact test for demographic and clinical data. Logistic regression analyses were conducted to determine the independent contribution of each possible predictor to eradication failure. PASW Statistics for Windows version 22.0 (IBM Co., Armonk, NY, USA) was used for statistical analysis. All statistical tests were two-tailed, and *p* values \< 0.05 were assumed to indicate statistical significance.

RESULTS
=======

Baseline characteristics of the study population
------------------------------------------------

Thirteen cases among the total of 203 patients did not participate. After receiving CAM-based triple therapy, 10 cases were lost to follow-up, one case was non-compliant, and two cases discontinued treatment owing to severe adverse events. Eventually, 190 patients were analyzed ([Fig. 1](#f1-kjim-2018-054){ref-type="fig"}). The baseline characteristics of all the participants are summarized in [Table 1](#t1-kjim-2018-054){ref-type="table"}.

Eradication rates and adverse events
------------------------------------

The overall eradication rates of CAM-based standard triple therapy according to ITT and PP analyses were 64.0% (130/203 patients) and 68.4% (130/190 patients), respectively ([Table 1](#t1-kjim-2018-054){ref-type="table"}). The frequency of adverse events is shown in [Table 2](#t2-kjim-2018-054){ref-type="table"}. The most frequent adverse event was metallic taste (65/190, 34.2%). Diarrhea, nausea, epigastric discomfort, urticaria, and headache followed. The adverse events were not different between the success group and failure group. Among 60 patients with first eradication failure, 53 patients received 10 days of bismuth-containing quadruple therapy. In 48 patients, the *H. pylori* infection was eradicated with a quadruple therapy (48/53, 90.6%) ([Fig. 1](#f1-kjim-2018-054){ref-type="fig"}).

CAM resistance
--------------

The rate of CAM resistance was 17.4% (33/190 cases) ([Table 1](#t1-kjim-2018-054){ref-type="table"}). The A2143G mutation was predominantly observed (30/33 cases, 90.9%). Two cases (6.1%) had A2142G mutation, and one case had a dual point mutation at A2142G and A2143G. All patients with CAM resistance revealed eradication failure ([Table 3](#t3-kjim-2018-054){ref-type="table"}). The frequency of CAM resistance was different between females (20/total 101 patients, 19.8%) and males (13/total 89 patients, 14.6%), but the difference did not reach statistical significance (*p* = 0.087).

*CYP2C19* genotype
------------------

Analysis of the *CYP2C19* genotypes showed that the RM genotype was present in 40/190 cases (21.0%), IM genotype in 75/190 cases (39.5%), and PM genotype in 75/190 cases (39.5%). There were no statistically significant differences among the three genotypes in *H. pylori* eradication (*p* = 0.682) ([Table 3](#t3-kjim-2018-054){ref-type="table"}).

Factors affecting eradication failure
-------------------------------------

The clinical characteristics of the eradication success group and failure group are shown in [Table 3](#t3-kjim-2018-054){ref-type="table"}. In univariate analysis, there were no statistically significant differences in clinical parameters except for female gender. CAM resistance was detected in 33/190 (17.4%) of cases and their eradication rate was zero (0/33 cases). In multivariate logistic regression analysis, female gender (odds ratio \[OR\], 1.73; 95% CI, 1.15 to 4.251; *p* = 0.016) and CAM resistance (OR, 19.13; 95% CI, 9.354 to 35.094; *p* \< 0.001) were identified as powerful predictive factors of eradication failure ([Table 4](#t4-kjim-2018-054){ref-type="table"}).

DISCUSSION
==========

The rate of *H. pylori* eradication by the CAM-based triple regimen has been decreasing in the past decades in Korea \[[@b18-kjim-2018-054]\]. In this study, we aimed to analyze the several factors associated with eradication failure; especially we focused on CAM resistance and the *CYP2C19* genotype. Interestingly, in our study, all patients with CAM resistance showed eradication failure. In several previous studies, patients treated with the CAM-based triple regimen showed an approximately 20% to 22% eradication rate \[[@b19-kjim-2018-054],[@b20-kjim-2018-054]\]. In those studies, resistance to CAM was evaluated using the agar dilution method. In contrast, our study used dual-priming oligonucleotide PCR to identify the point mutation, with higher specificity for detection of CAM resistance.

The Maastricht V/Florence Consensus Report in 2016 stated that PPI-CAM-amoxicillin triple therapy without a prior susceptibility test should be reconsidered in a region where the CAM resistance rate is higher than 15% \[[@b15-kjim-2018-054]\]. In our study, the CAM resistance was 17.4%. In another recent Korean study, the CAM resistance rate was above 20% \[[@b14-kjim-2018-054]\]. Considering that the CAM resistance rate was over 15%, alternative regimens are needed as the first-line treatment in Korea.

CAM resistance is related to A2142G, A2143G, or A2142C point mutations in the 23S rRNA of *H. pylori*, which decrease the affinity of CAM binding to the ribosome. Among the three point mutations, the A2143G point mutation is the major cause of resistance \[[@b21-kjim-2018-054],[@b22-kjim-2018-054]\]. In our study, A2143G rather than A2142G was also found to be the most prevalent mutation attributed to CAM resistance.

We examined a *CYP2C19* polymorphism to find the effect of PPI pharmacokinetics on *H. pylori* eradication. Depending on the *CYP2C19* genotype, the effect of PPI prescription on the eradication rate can vary. By contrast to the first-generation PPIs (e.g., omeprazole, pantoprazole, and lansoprazole), the second-generation PPIs (e.g., esomeprazole and rabeprazole) are not affected by *CYP2C19* metabolism \[[@b23-kjim-2018-054]-[@b25-kjim-2018-054]\]. There are a few studies on *CYP2C19* genetic variations and the eradication rate in Korea. One study revealed that the eradication rate of an esomeprazole-based regimen is higher (88.3%) than that of a pantoprazole-based regimen (82.6%) after adjustment for the *CYP2C19* genotype. Nonetheless, the differences were not statistically significant \[[@b26-kjim-2018-054]\]. In our study, all the patients were treated with pantoprazole because we believe that pantoprazole has higher antacid secretory efficacy than omeprazole does \[[@b27-kjim-2018-054]\]. Consequently, the eradication rate was not significantly influenced by the *CYP2C19* genotype. Nevertheless, it is possible that if we had treated the patients with omeprazole instead of pantoprazole, the results might have been different.

There are several reports that female gender can influence *H. pylori* eradication \[[@b28-kjim-2018-054],[@b29-kjim-2018-054]\]. One study suggested that there might be a difference in gastric physiology between males and females \[[@b30-kjim-2018-054]\]. Another study indicates that females are preferentially infected with the *H. pylori* strain with A2143G mutation, and thus the point mutation can contribute to the eradication failure \[[@b31-kjim-2018-054]\]. Our study showed that the female gender is an unfavorable factor affecting eradication. We found that females had a higher CAM resistance rate compared with males, but the difference was not significant (*p* = 0.087). The cause of gender differences in the eradication rate needs further research.

Cigarette smoking has been reported as a contributing factor of *H. pylori* eradication failure because of decreased blood flow to the gastric mucosa and stimulation of acid secretion. Furthermore, cigarette smoking provokes acid secretion and thus reduces the activity of acid-sensitive antibiotics (e.g., amoxicillin) \[[@b30-kjim-2018-054]\]. In the present study, however, we did not find an association between current cigarette smoking and eradication failure.

It has been reported that age can affect the eradication rate. Elderly patients with atrophic gastritis followed by decreased gastric acid secretion show a higher eradication rate \[[@b32-kjim-2018-054],[@b33-kjim-2018-054]\]. In the present study, age was not significantly associated with eradication outcomes.

Several studies have assessed the possible association between *H. pylori* and alcohol intake. Of note, one study showed that alcoholic beverages have some bactericidal activity. For this reason, regular wine (1 glass/day) or beer (0.5 pint/day) consumption was found to prevent *H. pylori* infection \[[@b34-kjim-2018-054]\]. In addition, some studies have indicated that alcohol consumption contributes to the efficacy of *H. pylori* eradication \[[@b35-kjim-2018-054],[@b36-kjim-2018-054]\]. Nonetheless, self-reported alcohol consumption is not accurate. This inaccuracy is a possible limitation of our study and studies by others. We could not find any association between alcohol intake and eradication efficacy.

Underlying chronic diseases such as hypertension and diabetes were occasionally reported to contribute to eradication failure, but the results were inconsistent, and the evidence was limited \[[@b37-kjim-2018-054],[@b38-kjim-2018-054]\].

Our study has some limitations. First, we included only the group of chronic gastritis, but not other gastroduodenal-disease groups. A further study including various gastroduodenal diseases is needed in the future. Second, we used only a CAM resistance test by means of a dual-priming oligonucleotide system. We did not perform amoxicillin resistance test. The resistance rate of amoxicillin in Korea has increased from 7.4% in 2008 to 17.2% in 2013 \[[@b11-kjim-2018-054]\]. Nevertheless, amoxicillin resistance had little or no effect on *H. pylori* eradication. Furthermore, the eradication rate was found to be 100% in a CAM-sensitive and amoxicillin-resistant *H. pylori* strain in a Korean population \[[@b8-kjim-2018-054],[@b39-kjim-2018-054]\]. In addition, a recent Korean study revealed that eradication failure was not significantly affected by amoxicillin resistance \[[@b14-kjim-2018-054]\]. Considering the other investigators' results, we assumed that doing only the CAM resistance test without an amoxicillin resistance test would not affect our results strongly.

Third, we treated the patients with one type of PPIs, pantoprazole. Our result is not sufficient to confirm irrelevance of the *CYP2C19* genotype for eradication failure and because pantoprazole is less affected by *CYP2C19* metabolic pathway than omeprazole is.

In conclusion, CAM resistance and female gender can affect the failure of *H. pylori* eradication with the CAMbased standard triple therapy in patients with chronic gastritis. A CAM resistance test before treatment is needed for improvement of the eradication rate and for reducing the overuse of antibiotics. Additionally, we propose that the CAM-based triple therapy should be replaced by some other first-line treatment not including CAM in high CAM resistance countries such as Korea.

KEY MESSAGE
===========

1\. The eradication rate of a clarithromycin-based triple regimen has decreased to an unacceptable level in Korea. We found that clarithromycin resistance is the most powerful predictive factor of *Helicobacter pylori* eradication failure in Korea.

2\. To increase the rate of successful eradication, new treatment guidelines and an appropriate treatment strategy are necessary.
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###### 

Demographic and clinical characteristics of all the patients (n = 190)

  Variable                   Value
  -------------------------- --------------------
  Age, yr                    55.4 ± 10.2
  Male:Female ratio          89:101 (46.8:53.2)
  Cigarette smoking          31 (16.3)
  Alcohol intake             65 (34.2)
  High salt diet             74 (38.9)
  Family history of GC       23 (12.1)
  Underlying disease         
   Hypertension              49 (25.8)
   Diabetes                  15 (7.9)
  Body mass index, kg/m^2^   23.8 ± 3.0
  Endoscopic findings        
   Non-atrophic gastritis    71 (37.4)
   Atrophic gastritis        119 (62.6)
  CAM mutation               33 (17.4)
   A2142G only               2 (6.1)
   A2143G only               30 (90.9)
   A2142G + A2143G           1 (3.0)
  *CYP2C19* genotype         
   PM                        74 (38.9)
   IM                        75 (39.5)
   RM                        41 (21.6)
  Eradication rate           
   ITT analysis              130/203 (64.0)
   PP analysis               130/190 (68.4)

Values are presented as mean ± SD or number (%).

GC, gastric cancer; CAM, clarithromycin; PM, poor metabolizer; IM, intermediate metabolizer; RM, rapid metabolizer; ITT, intention-to-treat; PP, per-protocol.

###### 

The frequency of adverse events in eradication success and failure groups

  Variable                Success group (n = 130)   Failure group (n = 60)   *p* value
  ----------------------- ------------------------- ------------------------ -----------
  None                    48 (36.9)                 17 (28.3)                0.324
  Metallic taste          67 (51.5)                 34 (56.7)                0.535
  Diarrhea                18 (13.8)                 8 (13.3)                 1.000
  Nausea                  5 (3.8)                   1 (1.7)                  0.667
  Epigastric discomfort   7 (5.4)                   6 (10.0)                 0.353
  Urticaria               3 (2.3)                   2 (3.3)                  0.652
  Headache/dizziness      8 (6.2)                   7 (11.7)                 0.247

Values are presented as number (%).

###### 

Clinical characteristics in eradication success and failure groups

  Variable                  Success group (n = 130)   Failure group (n = 60)   *p* value
  ------------------------- ------------------------- ------------------------ -----------
  Age, yr                   55.3 ± 10.3               55.5 ± 10.1              0.911
  Male:Female ratio         68:62 (52.3:47.7)         21:39 (35.0:65.0)        0.039
  Cigarette smoking         24 (18.5)                 7(11.7)                  0.334
  Alcohol intake            50 (38.5)                 15 (25.0)                0.098
  High salt diet            49 (37.7)                 25 (41.7)                0.717
  Family history of GC      14 (10.8)                 9 (15.0)                 0.554
  Underlying disease                                                           
   Hypertension             36 (27.7)                 13 (21.7)                0.481
   Diabetes                 13 (10.8)                 1 (1.7)                  0.061
  BMI, kg/m^2^              23.8 ± 2.9                23.9 ± 3.2               0.902
  Endoscopic findings                                                          0.728
   Non-atrophic gastritis   47 (36.2)                 24 (40.0)                
   Atrophic gastritis       83 (63.8)                 36 (60.0)                
  CAM mutation              0                         33 (55.0)                \< 0.001
  *CYP2C19* genotype                                                           0.733
   PM                       52 (40.0)                 22 (36.7)                
   IM                       52 (40.0)                 23 (38.8)                
   RM                       26 (20.0)                 15 (21.6)                

Values are presented as mean ± SD or number (%).

GC, gastric cancer; BMI, body mass index; CAM, clarithromycin; PM, poor metabolizer; IM, intermediate metabolizer; RM; rapid metabolizer.

###### 

Logistic regression analysis for *Helicobacter pylori* eradication failure

  Variable         Adjusted OR   95% CI          *p* value
  ---------------- ------------- --------------- -----------
  Female sex       1.730         1.151--4.251    0.016
  CAM resistance   19.132        9.354--35.094   \< 0.001

OR, odds ratio; CI, confidence interval; CAM, clarithromycin.

[^1]: These authors contributed equally to this work.
